UK patent changes could attract more new drug trials
This article was originally published in SRA
New UK legislation is expected to come into force in October that will level the playing field between originator and generic pharmaceutical companies in the area of clinical trials, and could help to make the UK more attractive as a location to conduct studies of new drugs.
You may also be interested in...
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
France is exploring the use of hydroxychloroquine and lopinavir/ritonavir in COVID-19, but only in hospitalized patients and in clinical trials, and has banned all exports of the products to avoid possible shortages.